An Exploratory Clinical Study of Anti-CD19/BCMA Chimeric Antigen Receptor NK Cell Injection in the Treatment of IgA Nephropathy

NCT06926985 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Due to limitation of production capacity

Conditions

IgA Nephropathy (IgAN)

Interventions

BIOLOGICAL: anti-CD19/BCMA CAR NK cells

Sponsor

Jieyang People's Hospital